Revive Therapeutics Advances Bucillamine for Long COVID

Revive Therapeutics (TSE:RVV) has released an update.

Revive Therapeutics is seeking FDA guidance on a Phase 2 clinical study for Bucillamine, which has shown promise as a treatment for long COVID. Recent research suggests that Bucillamine, a thiol-based drug with anti-inflammatory and antiviral properties, could significantly improve long COVID symptoms, with the company leveraging findings from its prior study showing positive effects in COVID-19 patients. With the economic impact of long COVID potentially reaching $3.7 trillion, Revive Therapeutics’ progress in this area could be of considerable interest to investors and those affected by the condition.

For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.